<DOC>
	<DOCNO>NCT00187447</DOCNO>
	<brief_summary>The purpose study examine high dose indomethacin increase rate ductus arteriosus closure extremely premature infant without increase side effect . The long term objective find optimal dose indomethacin permanent closure Ductus prevent morbidity relate PDA complication surgical ligation .</brief_summary>
	<brief_title>Comparison 2 Different Indomethacin Dosing Protocols Treat Infants Delivered &lt; 28 Weeks Gestation With Persistent Patent Ductus Arteriosus</brief_title>
	<detailed_description>This study Phase II randomize , mask , control trial compare current standard dose indomethacin high dose closure PDA premature infant less 28 week gestation . Neonates ( &lt; 28 week gestation ) start indomethacin treatment ( initial 3-dose course : 0.2 , 0.1 , 0.1 mg/kg indomethacin ) within first 96 hr birth eligible trial continue Doppler evidence ductus patency third dose indomethacin . This group infants great 65 % chance develop symptomatic PDA surgical ligation even standard extend course indomethacin . Those infant fit exclusion criterion randomize either Standard Dose group Higher Dose group obtain consent . The infant randomized standard group receive 4th , 5th , 6th dose indomethacin ( 0.1 mg/kg ) 24 hr interval ( start 24 hr 3rd dose ) . The Higher Dose group infant deliver 26-27 week gestation receive 4th , 5th , 6th , 7th , 8th 9th dose indomethacin ( 0.1mg/kg ) 12 hr interval ( start 12 hr 3rd dose ) . The Higher Dose group infants 24-25 week gestation receive 4th , 5th , 6th , 7th , 8th 9th dose indomethacin ( 0.25mg/kg ) 12 hour interval ( start 12 hr 3rd dose ) . To keep study blind , standard group receive 3 extra dos saline match 3 additional dos give high dose group .</detailed_description>
	<mesh_term>Ductus Arteriosus , Patent</mesh_term>
	<mesh_term>Indomethacin</mesh_term>
	<criteria>1 . Newborn infant le 28 week gestational age treat indomethacin first 48 hour birth 2 . Presence patent ductus arteriosus ( PDA ) Doppler echocardiography second third dose indomethacin . 3 . Creatinine ≤1.8 mg/dl 4 . Platelets ≥ 50,000 1 . Chromosomal disorder . 2 . Major congenital anomaly . 3 . Contraindications indomethacin 1 . Necrotizing enterocolitis , clinical radiological evidence 2 . Evidence bleed diathesis evidence pulmonary hemorrhage , persistent ooze puncture site , grossly bloody stool ( Note : Infants intracranial hemorrhage enrol study ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>48 Hours</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>prematurity</keyword>
	<keyword>chronic lung disease</keyword>
	<keyword>necrotizing enterocolitis</keyword>
	<keyword>indomethacin</keyword>
	<keyword>ductus arteriosus</keyword>
</DOC>